H.R. 1193 — Reported in Senate

II Calendar No. 443 117th CONGRESS 2d Session H. R. 1193 IN THE SENATE OF THE UNITED STATES December 9, 2021Received May 25, 2022Read twice and referred to the Committee on Health, Education, Labor, and Pensions July 12, 2022Reported by Mrs. Murray, with an amendmentStrike out all after the enacting clause and insert the part printed in italic AN ACT To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes. 1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act. 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act (42 U.S.C. 285b et seq.) is amended by inserting after section 424C (42 U.S.C. 285b–7c) the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized under subsection (a) may be used to pursue the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) For other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of the enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of Centers for Disease Control and Prevention Part B of title III of the Public Health Service Act (42 U.S.C. 243 et seq.) is amended by inserting after section 312 the following section: 312A. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Upon availability of applicable data, projects carried out under subsection (a) may include— (1) continuing the activities at the Division for Heart Disease and Stroke Prevention, including those related to valvular heart disease; (2) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of valvular heart disease; and (3) enhancing surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. . 1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act. 2. HHS valvular heart disease activities (a) In general The Secretary of Health and Human Services (referred to in this section as the Secretary) shall, as appropriate, continue activities related to research, education, and awareness of valvular heart diseases. (b) NIH research related to valvular heart diseases (1) In general The Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, may support or conduct research regarding valvular heart diseases. (2) Support further research In order to improve information on, and understanding of, causation and risk factors for valvular heart diseases, research conducted or supported under this subsection for such diseases may include the following: (A) Use of advanced technological imaging and other relevant methods to generate data related to valvular heart diseases. (B) Assessing potential risk factors for sudden cardiac arrest or sudden cardiac death from valvular heart diseases. (C) Other activities, as appropriate, in order to improve the availability of information on, and advance research related to, valvular heart diseases. (3) Mitral valve prolapse workshop Not later than one year after the date of enactment of this Act, the Director of the National Heart, Lung, and Blood Institute shall, as appropriate, convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop recommendations for the identification and treatment of individuals with mitral valve prolapse, including such individuals who may be at risk for sudden cardiac arrest or sudden cardiac death. (c) Prevention activities to improve awareness of sudden cardiac death as a result of valvular heart diseases (1) In general The Secretary may carry out activities to increase education and awareness of valvular heart diseases in order to reduce the incidence of sudden cardiac death caused by such diseases. The Secretary may— (A) award grants or contracts to public or nonprofit private entities to carry out activities under this subsection; and (B) may directly, or through grants or contracts, provide technical assistance with respect to such activities. (2) Certain activities Upon availability of applicable data, projects carried out under paragraph (1) may include— (A) continuing activities at the Centers for Disease Control and Prevention related to valvular heart diseases; (B) improving the awareness of the public concerning any risk factors for, the symptoms of, and the public health impact of, valvular heart diseases; and (C) improving the availability of public health data and information, as appropriate, regarding cardiac arrests related to valvular heart diseases. (3) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to paragraph (1), give priority to entities seeking to carry out projects for populations most impacted by valvular heart diseases. (4) Coordination of activities The Secretary shall, as appropriate, ensure that activities under this section are coordinated with other agencies and offices of the Department of Health and Human Services that carry out activities regarding valvular heart diseases. (5) Best practices The Secretary shall, as applicable and appropriate, identify and disseminate best practices for relevant health care providers related to valvular heart diseases. (d) Authorization of appropriations For purposes of carrying out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2023 through 2027. July 12, 2022Reported with an amendment